Trial · NCT04721977
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 44
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Tucatinib + Capecitabine + Trastuzumab | 13 | 66 | 16 |
| other | Abdominal pain upper | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 6 | 66 | 6 |
| other | Cheilitis | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 4 | 66 | 4 |
| other | Constipation | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 6 | 66 | 6 |
| other | Diarrhoea | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 40 | 66 | 57 |
| other | Nausea | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 32 | 66 | 41 |
| other | Stomatitis | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 18 | 66 | 19 |
| other | Vomiting | Gastrointestinal disorders | Tucatinib + Capecitabine + Trastuzumab | 9 | 66 | 14 |
| other | Fatigue | General disorders | Tucatinib + Capecitabine + Trastuzumab | 9 | 66 | 13 |
| other | Malaise | General disorders | Tucatinib + Capecitabine + Trastuzumab | 13 | 66 | 18 |
| other | Oedema peripheral | General disorders | Tucatinib + Capecitabine + Trastuzumab | 4 | 66 | 4 |
| other | Pyrexia | General disorders | Tucatinib + Capecitabine + Trastuzumab | 8 | 66 | 9 |
| other | Hepatic function abnormal | Hepatobiliary disorders | Tucatinib + Capecitabine + Trastuzumab | 6 | 66 | 9 |
| other | COVID-19 | Infections and infestations | Tucatinib + Capecitabine + Trastuzumab | 9 | 66 | 9 |
| other | Nasopharyngitis | Infections and infestations | Tucatinib + Capecitabine + Trastuzumab | 5 | 66 | 6 |
| other | Paronychia | Infections and infestations | Tucatinib + Capecitabine + Trastuzumab | 10 | 66 | 10 |
| other | Accidental overdose | Injury, poisoning and procedural complications | Tucatinib + Capecitabine + Trastuzumab | 6 | 66 | 7 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Tucatinib + Capecitabine + Trastuzumab | 5 | 66 | 5 |
| other | Alanine aminotransferase increased | Investigations | Tucatinib + Capecitabine + Trastuzumab | 20 | 66 | 26 |
| other | Aspartate aminotransferase increased | Investigations | Tucatinib + Capecitabine + Trastuzumab | 16 | 66 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04721977/events